GlobeNewsWire
18 Dec 2025, 21:35 UTC · 45w ago
Impact · against what's priced in
Annovis is advancing its regulatory path for buntanetap in Parkinson's disease by launching an Open-Label Extension study to satisfy FDA patient exposure requirements. The inclusion of a Deep Brain Stimulation cohort further expands the drug's potential addressable market.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Annovis is launching an Open-Label Extension (OLE) study to help meet FDA patient exposure requirements for a future New Drug Application (NDA) submission.
More positive than 92% of claims this week
The OLE study for buntanetap in Parkinson's disease patients will begin enrollment in January 2026 with a target of 500 participants.
Continue reading
5 related stories
The launch of an OLE study targeting 500 participants helps Annovis reach the ~1,500 total treated patients required for an NDA submission, while the DBS cohort targets an underserved population.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 61% of claims this week
The study includes a specific cohort of patients who have received Deep Brain Stimulation (DBS) for at least 12 months to evaluate the interaction between buntanetap and surgical treatment.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is advancing its drug pipeline with a new study that helps meet FDA requirements for a future NDA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
−69.8%
Price is moving against the score
$1.11 vs $3.67 close before publication (Dec 18) · not market-adjusted
ANVS chart →
